Campus alert status is yellow: For the latest campus alert status, news and resources, visit

Search Close Search
Search Close Search
Page Menu

Joonsoo Kang




UMassMed Faculty Page


Title: Immunotherapy for T Cell-Mediated Autoimmune Diseases Using ITK Inhibitors. UMMS10-05; Patent Pending. 

  • The present disclosure is based, in part, on the discovery that interleukin-2-inducible T cell kinase (ITK) and CD28 signals regulate auto-reactive T cell trafficking and that organ-specific T cell mediated autoimmune diseases such as Type 1 diabetes and multiple sclerosis. Accordingly, the present specification provides methods of treating organ-specific T cell mediated autoimmune diseases by inhibiting ITK with a therapeutically effective amount of an ITK inhibitor, e.g., BMS509744, ibrutinib, 10n, 2-amino-5-(thioaryl)thiazole, 5 aminomethylbenzimidazole, 2-amino-5-[(thiomethyparyl]thiazole, and biaryl thiophene. 


Innovation TopicsSmall MoleculesType I DiabetesType II DiabetesImmunologyMultiple Sclerosis